Company intelligence / Profile preview

Transverse Medical

Denver, Colorado, United Statestransversemedical.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Transverse Medical has developed the POINT-GUARD™ device to provide full-brain cerebral embolic protection during structural heart procedures. The technology aims to minimize or eliminate procedural strokes by filtering cerebral embolic debris. The company recently raised over $10 million in Series B2 funding to advance its clinical and regulatory programs. No published clinical trial results were identified.

Therapeutic areas: Cardiovascular
Modalities: Medical device (cerebral embolic protection device)
Industry: Surgical Medical Devices

Drug pipeline

1 asset

POINT-GUARD

Phase 1

Indications: Stroke prevention during TAVR

Beyond the preview

Go deeper on Transverse Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transverse Medical.

Explore the full profile